Key points {#FPar1}
==========

Compared to trough-based vancomycin TDM, peak--trough-based vancomycin TDM was associated with a higher clinical success rate and less vancomycin dose requirements.Maintaining AUC~24~/MIC between 565 and 1256 has been associated with cure.

Introduction {#Sec1}
============

Therapeutic drug monitoring (TDM) of vancomycin is essential in ensuring the attainment of positive clinical outcomes and minimizing toxicity \[[@CR1]\]. Vancomycin clinical pharmacokinetic parameters exhibit large inter-individual variability even with identical dosing regimens \[[@CR2]\]. Traditionally, steady-state vancomycin peak (*C*~max,ss~) and trough (*C*~trough,ss~) concentrations were measured for vancomycin TDM. In 2009, a paradigm shift in clinical vancomycin dosing and monitoring practices emerged, following the release of a consensus guideline jointly by the American Society of Health-System Pharmacists (ASHP), the Society of Infectious Diseases Pharmacists, and the Infectious Disease Society of America (IDSA) \[[@CR3]\]. Based on limited clinical data and animal studies, vancomycin was considered 'concentration-independent' and thus *C*~max,ss~ monitoring was no longer recommended. Additionally, a 24-h area under the concentration--time curve (AUC~24~) to minimum inhibitory concentration (MIC) ratio (AUC~24~/MIC) of ≥ 400 was defined as the target surrogate to attain clinical effectiveness. These guidelines recommended *C*~trough,ss~ monitoring as a surrogate for achieving AUC~24~/MIC ≥ 400 with a value of 15--20 mg/L as an acceptable therapeutic range.

Published evidence after 2009 called into question the recommended target ratio (AUC~24~/MIC ≥ 400) \[[@CR4]\], as different AUC/MIC ratios have been found to achieve clinical effectiveness \[[@CR5]--[@CR7]\]. This reported variability in AUC/MIC breakpoints may be attributed to the genetic variability between methicillin-resistant *Staphylococcus aureus* (MRSA) strains across different geographical areas \[[@CR8]--[@CR18]\], the differences in MRSA site of infection, and the variability of the populations studied in terms of comorbidities and ethnicities \[[@CR19]\]. Hence, the generalizability of the published literature remains limited to different disease states, geographical regions, and populations. Furthermore, recent studies questioned the use of *C*~trough,ss~ as an indicator of AUC~24~/MIC optimal exposure, as discrepancies between optimal AUC~24~ exposures and the associated trough concentrations have been reported \[[@CR2], [@CR20]--[@CR24]\]. The superior clinical utility of multiple-concentration-based vancomycin dosing approaches compared to trough-only guided dosing has been suggested \[[@CR21]--[@CR23]\]. One of those approaches is peak--trough-based pharmacokinetic dosing \[[@CR20], [@CR23], [@CR25]\]. Collectively, these studies raised concerns regarding the optimal vancomycin AUC~24~/MIC breakpoint for cure, and the best vancomycin TDM approach that would result in the attainment of the optimal AUC~24~/MIC ratio associated with clinical effectiveness.

The use of vancomycin in the treatment of serious Gram-positive infections has become very challenging in Asia, including the Middle East and North Africa (MENA) region \[[@CR16], [@CR26], [@CR27]\]. A meta-analysis of 91 studies exploring the epidemiology of vancomycin intermediate-resistant *S.aureus* (VISA) strains during 1997 and 2014, reported higher VISA incidence rates in Asia, including MENA, compared to other regions \[[@CR26]\]. Given that suboptimal antimicrobial therapy of MRSA contributes to the emergence of resistant strains \[[@CR27]\], these findings highlight the potentially high prevalence of inadequate vancomycin treatment in MENA. This can be attributed to non-adherence to clinical practice guidelines or the limited generalizability of vancomycin AUC~24~/MIC targets reported elsewhere. Genetic and epidemiologic diversity between MRSA clones across various geographical regions and time-points have been reported worldwide, including MENA \[[@CR12]--[@CR18]\]. However, the currently applied vancomycin dosing nomograms in the MENA region are based on published Western vancomycin pharmacokinetic--pharmacodynamic targets, due to the lack of studies reporting MENA-specific targets. Expatriates from different MENA and Asian countries constitute the majority of Qatar's population, with nationals reported to be \< 15% \[[@CR28], [@CR29]\]. Therefore, we aimed to explore MENA-specific pharmacokinetic--pharmacodynamic vancomycin targets to understand the reasons for vancomycin treatment failures in the MENA region.

Although the 2009 consensus guidelines recommend trough-only monitoring \[[@CR3]\], to the best of our knowledge, no prospective randomized controlled trials (RCTs) have been conducted to compare the clinical and pharmacokinetic outcomes between the traditional peak--trough-based and the trough-only-based vancomycin TDM approaches. Additionally, the vancomycin AUC~24~/MIC cure breakpoint in MENA-specific populations and bacterial strains has not yet been studied. Therefore, this prospective parallel-group pragmatic multicenter RCT was conducted to compare the clinical and pharmacokinetic outcomes of peak--trough-based and trough-only-based vancomycin TDM approaches and to evaluate the relationship between vancomycin AUC~24~/MIC ratios and cure in the MENA population.

Methods {#Sec2}
=======

Study Design and Setting {#Sec3}
------------------------

A multicenter pragmatic two parallel-group RCT was conducted in three tertiary care hospitals under Hamad Medical Corporation (HMC) in Qatar---Al-Wakrah Hospital (AWH), Al-Khor Hospital (AKH), and Hamad General Hospital (HGH).

Study Population and Sample Size Calculation {#Sec4}
--------------------------------------------

Inclusion criteria included hospitalized adults (≥18 years) with suspected/confirmed staphylococcal or other Gram-positive infection requiring treatment with vancomycin for at least 3 days based on the attending physician's judgment. Exclusion criteria included renal instability \[abrupt absolute increase in serum creatinine (SCr) ≥ 0.5 mg/dL from baseline or a percentage increase in SCr ≥ 50% within 48 h\]; end-stage renal disease; transplant; immunosuppression; active malignancy; receiving antineoplastic agents; HIV or absolute neutrophil counts \< 1000 cells/mm^3^; vancomycin allergy; history of recurrent resistant peritonitis; administration of \< 4 doses of vancomycin or for \< 72 h; vancomycin administration for post-surgical infection prophylaxis; pregnancy; subjects not able to undergo blood sampling per clinician judgment; anuria (urine output \< 100 mL/day); symptomatic anemia; and hemoglobin \< 8 g/dL.

Sample size was calculated a priori to be 120 subjects (60 subjects per arm) \[[@CR30]\]. The primary endpoint used for sample size calculation was clinical effectiveness (therapeutic cure). Based on the meta-analysis of Ye et al., we assumed 85% cure rates in the peak--trough-based vancomycin TDM arm versus 60% cure rates in the control arm \[[@CR31]\]. An attrition rate of 20%, a significance level of 5%, and a power of 80% were considered in the a priori power analysis \[[@CR30]\]. Given the unexpectedly slow recruitment rate, interim analysis was conducted at 7 months. Statistically significant differences in the primary study outcome of clinical effectiveness were achieved. Thus, the study was ended after the enrollment of 65 subjects since a significant difference was detected in the primary study outcome.

Randomization and Blinding {#Sec5}
--------------------------

Participants who provided informed consent and fulfilled the eligibility criteria were randomly assigned to one of the two study groups---(1) peak--trough (intervention) group or (2) trough-only (control) group. An allocation ratio of 1:1 was applied using a computer-generated list of random numbers. Due to the pragmatic nature of this trial, blinding was not possible since the treating clinical team needed to apply the dose change recommendations after justification. Thus, the method used for dose adjustment was revealed as part of justification, when requested by the attending physician.

Study Interventions {#Sec6}
-------------------

All subjects were initiated on vancomycin initial/empiric doses by the attending physician prior to enrollment in the study \[[@CR3], [@CR32]--[@CR35]\]. Initiation or discontinuation of vancomycin treatment was the sole decision of the treating primary team and was not influenced by the study investigators. This trial was pragmatic in nature; thus, subjects were treated as part of routine care. No co-medications, medical procedures, dietary restrictions or restrictions to participation in other concurrent research were applied.

In the two study arms, target *C*~trough,ss~ was as per the recommendations of the HMC institutional guidelines and the clinical practice guidelines: \> 10 mg/L for less serious infections such as skin and soft tissue infections (SSTIs); and 15--20 mg/L for complicated infections such as bacteremia, infective endocarditis, osteomyelitis, meningitis, hospital-acquired pneumonia, and serious SSTI (e.g., necrotizing fasciitis) caused by *S. aureus* \[[@CR3]\]. Creatinine clearance (CL~CR~) was calculated using the Cockcroft--Gault equation \[[@CR36]\]. In patients with declined renal function or at risk of nephrotoxicity, the lower end *C*~trough,ss~ targets were used. In the intervention arm, target *C*~max,ss~ was 20--40 mg/L \[[@CR1]\], stratified according to the patient's renal function. In patients with normal CL~CR~, *C*~max,ss~ ≥ 30--35 mg/L was targeted. Otherwise, a lower *C*~max,ss~ was used, considering clinical judgment and dosing feasibility. This range was used with the objective of sufficient infected tissue penetration while preventing adverse drug reactions (ADRs), by accounting for possible declined renal function and other nephrotoxicity risk factors \[[@CR1]\].

### Blood Specimen Collection for Initial Vancomycin Concentrations {#Sec7}

In both study arms, five initial vancomycin blood samples were collected through venipuncture. Routine vancomycin trough concentrations were collected 30 min before the fourth dose (*C*~trough,ss1~). For the study purpose, four vancomycin blood samples (10 mL of blood for each) were obtained at 1--2 h post fourth dose infusion (*C*~max,ss~), 30 min before the fifth dose (*C*~trough,ss2~), and two concentrations in between the peak and trough concentrations (C~1~, C~2~) after the fourth dose (i.e., at steady state). For instance, if the patient was receiving a 12-hourly vancomycin regimen, C~1~ and C~2~ were drawn at 4 h and 8 h post fourth dose infusion. On the other hand, if the patient was taking an 8-hourly regimen, C~1~ and C~2~ were drawn at 4 h and 6 h post fourth dose infusion.

### Biochemistry and Microbiology Specimen Analysis {#Sec8}

Vancomycin blood specimens were collected and analyzed at HMC biochemistry laboratories using particle-enhanced turbidimetric inhibition immunoassay (PETINA) \[[@CR37]\]. Specimens from HGH and AKH were analyzed using the Architect c16000 (Abbott, USA) analyzer \[[@CR38]\], while specimens from AWH were analyzed using the UniCel^®^ DxC 600 (Beckman Coulter, USA) analyzer \[[@CR39]\]. To determine vancomycin susceptibilities, microbiology cultures were processed using the broth microdilution test technique (BD Phoenix AP, USA) \[[@CR40], [@CR41]\]. Our institution uses the vancomycin MRSA susceptibly breakpoint (≤ 2 mg/L) set out by the Clinical and Laboratory Standards Institute (CLSI). For definitive sensitive cultures, the institutional laboratories reported MICs as '\< 1 mg/L' or '= 1 mg/L'. A survey of institutional vancomycin MIC of sensitive MRSA isolates collected between April 2015 and January 2016 showed that the MICs for most cultures were reported as 1 mg/L. Thus, we assumed an MIC of 1 mg/L for all specimens in this study.

### Trough-Only-Based Vancomycin Dosing Adjustment {#Sec9}

In the control arm, only trough concentrations were considered for dosing adjustments. If the target trough was not achieved, a new dose or a new dosing interval was calculated using trough-only linear method equations (Eqs. [1](#Equ1){ref-type=""}, [2](#Equ2){ref-type=""}) as below \[[@CR1], [@CR42], [@CR43]\], where *C*~trough,ss~ is the target new steady-state trough concentration; *C*~t~ is the current trough concentration; *D*~old~ is the old dose that resulted in *C*~t~; *τ*~old~ is the old dosing interval that resulted in *C*~t~; and *τ*~new~ is the new dosing interval. Either the 'dose-only change' or the 'dosing interval-only' change equation was used based on clinical feasibility and practicality.
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### Peak--Trough-Based Vancomycin Dosing Adjustment {#Sec10}

Based on both the peak and trough vancomycin concentrations, a patient's individualized pharmacokinetic parameters were calculated and used in dose adjustment calculations. If either the peak or trough or both concentrations were non-therapeutic, a new vancomycin dosing regimen was calculated and administered. Intravenous (IV) bolus equations (Eqs. [3](#Equ3){ref-type=""}--[7](#Equ7){ref-type=""}) were used provided that the vancomycin infusion time was short relative to the patient-specific vancomycin half-life \[[@CR1], [@CR42]\]. If this assumption was not valid due to augmented renal clearance (ARC) or infusion durations \> 1 h, IV intermittent infusion equations (Eqs. [8](#Equ8){ref-type=""}--[13](#Equ13){ref-type=""}) were used as below \[[@CR1], [@CR42]\]; where *K*~e~ is the elimination rate constant; *k*~0~ is the infusion rate; *t*~1/2~ is the half-life; *V* is the volume of distribution; Cl is the clearance; *D* is the dose; C~1~ is the vancomycin concentration at time *t*~1~; C~2~ is the vancomycin concentration at time *t*~2~; *C*~p~ is the peak concentration; C~t~ is the trough concentration; *C*~max,ss~ is the target steady-state peak concentration; *C*~*t*rough,ss~ is the target steady-state trough concentration; *τ* is the dosing interval; and *t*′ is the infusion duration.
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### Post-Dose Adjustment Vancomycin Monitoring {#Sec11}

After any dose adjustment, the time to new steady state was calculated and post-dose adjustment peak and trough vancomycin concentrations were measured. If measured vancomycin concentrations were not at target levels, additional dose adjustments were applied as discussed above. Otherwise, vancomycin peak and trough concentration monitoring continued every 24--48 h.

Study Endpoints {#Sec12}
---------------

### Primary Outcome Measures {#Sec13}

The primary outcome measures of clinical effectiveness were (1) vancomycin AUC~24~/MIC cure breakpoint; (2) therapeutic cure (composite endpoint); and (3) therapeutic failure (composite endpoint). Therapeutic cure was defined as clinical cure and/or microbiologic cure \[[@CR6], [@CR44]--[@CR46]\]. Clinical cure was defined as the absence of infection signs/symptoms without the need for additional antibiotic treatment. Microbiologic cure was defined as negative blood cultures at 5 days after vancomycin treatment initiation. Therapeutic failure included at least one of the following \[[@CR6], [@CR44]--[@CR46]\]---clinical failure, microbiologic failure, premature discontinuation due to ADR or all-cause mortality. Clinical failure was defined as insufficient clinical response to initial vancomycin therapy necessitating antibiotic change. Microbiological failure was defined as a positive culture at ≥ 5 days after initiation of vancomycin treatment. Neutropenia was defined as absolute neutrophil counts \< 1000/μL \[[@CR47], [@CR48]\]. Nephrotoxicity was defined as 'a minimum of two or three consecutive SCr increases (defined as an increase of 0.5 mg/dL or at least 50% increase from baseline) after several days of vancomycin therapy' \[[@CR3]\]. All-cause mortality was defined as death from any cause during enrollment in the trial.

### Secondary Outcome Measures {#Sec14}

Secondary outcomes included (1) length of hospital stay (LOS); (2) number of dose adjustments required; (3) cumulative vancomycin doses received; and (4) duration of vancomycin treatment.

Statistical Analysis {#Sec15}
--------------------

Intention-to-treat analysis was applied. Descriptive and inferential statistics were conducted (SPSSv.23; IBM^®^, Armonk, NY, USA) to compare the differences in clinical outcomes between the intervention (i.e., peak--trough-based vancomycin TDM approach) and the control (i.e., trough-only-based vancomycin TDM approach) arms. Skewness test was applied to ensure normality of data (choice of parametric vs nonparametric tests). For comparison between the groups, Student's *t*-test, Mann--Whitney *U*-test or chi-squared test was used as appropriate. All comparisons were carried out using an a priori significance level of 0.05 (two-sided tests). AUCs were calculated using the nonlinear mixed-effects population pharmacokinetics modeling approach (NONMEM v.7.3, ICON, USA) \[[@CR49]\]. Classification and regression tree (CART) analysis was conducted using SPSS v.23 (IBM^®^; Armonk). AUC~24~/MIC, vancomycin cumulative doses, treatment duration, infected physiologic compartment, ethnicity, CL~CR~ and TDM approach were tested against clinical effectiveness. To assess the predictive accuracy of the generated models, misclassification risk estimates with standard error were used \[[@CR50]\].

Results {#Sec16}
=======

Baseline Characteristics of the Study Participants {#Sec17}
--------------------------------------------------

Sixty-five subjects were enrolled (35 in the trough-only-based vancomycin TDM group and 30 in the peak--trough-based vancomycin TDM group). Baseline characteristics were similar between the study groups and are summarized in Table [1](#Tab1){ref-type="table"}. Central nervous system infections (*n* = 15, 23.1%), lower respiratory tract infections (*n* = 16, 24.6%) and sepsis or septic shock (*n* = 11, 16.9%) were the most frequently occurring infections. Vancomycin was initiated as a definitive treatment in more than half of the cases (*n* = 35, 53.3%). Of the identified bacteria (*n* = 35), MRSA (*n* = 17, 48.6%), MSSA (*n * = 8, 22.9%), *S. epidermidis* (*n* = 5, 14.3%) and *Enterococcus faecium* (*n* = 4, 11.4%) constituted the most frequent positive microbiologic cultures. Approximately half of the study participants were critically ill and hospitalized in critical care units (*n* = 31, 47.7%). Physician-prescribed initial vancomycin dosing regimens were comparable between the study groups.Table 1Baseline characteristics of the study participantsVariableTrough-monitoring groupPeak--trough-monitoring group(*n* = 35)(*n* = 30)Age (years), mean ± SD41.7 ± 19.5642.4 ± 14.47BMI (kg/m^2^), median \[IQR\]26.7 \[5.2\]25.4 \[7.8\]ABW (kg), median \[IQR\]73.1 \[23.6\]70 \[19.3\]Height (cm), median \[IQR\]169 \[13\]168 \[10.5\]Gender, *n* (%) Male30 (85.7)22 (73.3) Female5 (14.3)8 (26.7)Ethnicity, *n* (%) MENA23 (65.7)8 (26.7) Asian (non-MENA)11 (31.4)20 (66.7) African (non-MENA)1 (2.9)2 (6.7)Hospitalization ward, *n* (%) Intensive care units^a^13 (37.1)18 (60) Burns unit2 (5.7)0 (0) Medical ward11 (31.4)9 (30) Surgical/orthopedic ward9 (25.7)3 (10)Diagnosis, *n* (%) CNS infection^b^5 (15.3)10 (33.3) Bacteremia4 (11.4)2 (6.7) Skin and soft tissue infection4 (11.4)4 (13.3) Bone and joint infection6 (17.1)2 (6.7) Sepsis/septic shock5 (14.3)6 (20) Lower respiratory tract infection7 (20)5 (16.7) Infective endocarditis1 (2.9)0 (0) Intra-abdominal infection3 (8.6)1 (3.3)Infected physiologic compartment, *n* (%) CNS compartment^b^5 (14.3)10 (33.3) Blood compartment^c^13 (37.1)9 (30) Lung compartment7 (20)5 (16.7) Other tissues^d^10 (28.6)6 (20)Vancomycin treatment type, *n* (%) Empiric16 (45.7)14 (46.7) Definitive19 (54.3)16 (53.3)Positive microbiologic cultures, *n* (%) MRSA8 (42.1)9 (56.3) MSSA5 (26.3)3 (18.6) *S. epidermidis*4 (21.1)1 (6.3) *S. constellatus*1 (5.3)0 (0) *E. faecium*1 (5.3)3 (18.8)Pre-enrollment vancomycin treatment details Pre-enrollment days on vancomycin treatment, median \[IQR\]2 \[0.5\]1.5 \[1\] Dose (mg/dose), median \[1QR\]1000 \[0\]1000 \[0\] Dose (mg/kg/dose), median \[IQR\]14.3 \[5.6\]14.6 \[3.7\] Total daily dose (mg/day), median \[IQR\]2000 \[1000\]2000 \[125\] Total daily dose (mg/kg/day), median \[IQR\]28.6 \[16.5\]29.2 \[7.4\] Cumulative doses received (mg), median \[IQR\]4000 \[1250\]5000 \[2063\] Cumulative doses received (mg/kg), median \[IQR\]59.4 \[25.04\]66.8 \[29.6\]Laboratory parameters White blood cells (×10^9^ IU/L), mean ± SD13.36 ± 7.912.8 ± 6.02 Hemoglobin (g/dL), median \[IQR\]11.53 \[2.32\]11.7 \[4.15\] Neutrophils (×10^9 ^IU/L), median \[IQR\]8 \[9.8\]8.2 \[7.7\] SCr (µmol/L), median \[IQR\]65 \[36\]67 \[30\] Concomitant antibiotics, *n* (%)18 (51.4)22 (55) Beta-lactams9 (25.7)9 (30) Carbapenems10 (15.4)11 (16.9) Cephalosporins9 (25.7)12 (40) Clindamycin2 (5.7)1 (3.3) Linezolid0 (0)4 (13.3) Rifampicin1 (2.9)1 (3.3) Concomitant nephrotoxic agents, *n* (%)12 (34.3)12 (40) Amphotericin B0 (0)2 (6.7) NSAIDs8 (22.9)10 (33.3) ACEI/ARBs4 (11.1)1 (3.3) Loop/thiazide diuretics4 (11.4)6 (20) Acyclovir1 (2.9)0 (0)Comorbidities, *n* (%) Diabetes mellitus6 (17.1)8 (26.7) Chronic kidney disease1 (2.9)2 (6.7) Hypertension7 (20)11 (36.7) Coronary vascular disease2 (5.7)4 (13.3) Heart failure1 (2.9)2 (6.7)*BMI* body mass index, *ABW* actual body weight, *MENA* Middle East and North Africa, *MRSA* methicillin-resistant *S. aureus, MSSA* methicillin-sensitive *S. aureus*^a^Includes trauma, medical and surgical intensive care units^b^Involves meningitis, encephalitis and ventriculitis^c^Includes blood, intra-abdominal and cardiac infections^d^Includes skin, soft tissue, bone and joint infections

Clinical Outcomes of Peak--Trough-Based Versus Trough-Only-Based Vancomycin TDM Approaches {#Sec18}
------------------------------------------------------------------------------------------

Peak--trough-based vancomycin TDM was significantly associated with higher infection cure rates compared to trough-only-based vancomycin TDM \[*p* value = 0.02; Table [2](#Tab2){ref-type="table"}\]. Compared to the control group (trough-only-based TDM group), the intervention group (peak--trough-based TDM group) required non-statistically significant shorter duration of vancomycin treatment and hospitalization by 0.5 days and 4.5 days, respectively \[*p* value \> 0.05; Table [2](#Tab2){ref-type="table"}\]. No statistically significant differences were observed for other safety endpoints between the two monitored groups \[*p* value \> 0.05; Table [2](#Tab2){ref-type="table"}\].Table 2Clinical outcomes of peak--trough-based versus trough-only-based vancomycin therapeutic drug monitoring approachesVariableTrough-only-monitoring groupPeak--trough-monitoring group*p* value^a^(*n* = 35)(*n *= 30)Vancomycin treatment efficacy outcomes, *n* (%) Therapeutic cure17 (48.6)23 (76.7)0.020 Therapeutic failure18 (51.4)7 (23.3)Vancomycin treatment safety outcomes, *n* (%) Neutropenia3 (8.6)1 (3.3)0.381 Nephrotoxicity1 (2.9)1 (3.3)0.912 All-cause mortality, *n* (%)3 (8.6)2 (6.7)0.774 Length of hospitalization (days), median \[min--max\]20 \[6--117\]15.5 \[4--68.9\]0.320 Total duration on vancomycin treatment (days), median \[min--max\]7 \[1--28\]6.5 \[1--32\]0.319^a^Chi-squared test or Mann--Whitney *U*-test

Clinical Pharmacokinetic Outcomes of Peak--Trough-Based Versus Trough-Only-Based Vancomycin TDM Approaches {#Sec19}
----------------------------------------------------------------------------------------------------------

Initial peak and trough vancomycin serum concentrations were not therapeutic in 30.2% (*n* = 19) and 80% (*n* = 52) of cases, respectively (Table [3](#Tab3){ref-type="table"}). Individual vancomycin clinical pharmacokinetic parameters were comparable between the study groups (Table [3](#Tab3){ref-type="table"}). Patients enrolled in the peak--trough-based group received TDM earlier than the trough-only-based group by 0.5 days \[*p* value = 0.001\]. Vancomycin dosing requirements significantly differed between the two vancomycin TDM approaches; compared to the trough-only-based vancomycin TDM group, the peak--trough-based group required lower average vancomycin single doses and total daily doses by 370 mg/dose and 927 mg/day, respectively \[*p* value \< 0.05; Table [3](#Tab3){ref-type="table"}; Fig. [1](#Fig1){ref-type="fig"}\]. Despite the similar duration on vancomycin treatment between the study groups, the trough-only-based vancomycin TDM recipients received clinically significant higher median cumulative vancomycin doses by 6,522 mg \[*p* value \> 0.05; Table [3](#Tab3){ref-type="table"}\]. Patients who received trough-only-based vancomycin TDM required more dose adjustments to achieve target serum concentrations compared to the intervention group \[*p* value \> 0.05; Table [3](#Tab3){ref-type="table"}\]. Furthermore, the trough-only-based monitoring was associated with recommended vancomycin dosing regimens of relatively low dosing frequencies and large single doses, necessitating longer infusion durations that exceeded 1 h (Table [3](#Tab3){ref-type="table"}). The compared TDM approaches resulted in statistically and clinically significant different peak concentrations; peak--trough-based vancomycin dose adjustments compared to trough-only based vancomycin dose adjustments resulted in achievement of target peaks for 94.1% versus 69% of the time, respectively \[*p* value = 0.006; Table [3](#Tab3){ref-type="table"}\]. Interestingly, peak--trough-based vancomycin doses resulted in similar rates of therapeutic troughs and AUCs compared to trough-only-based vancomycin doses (Table [3](#Tab3){ref-type="table"}).Table 3Clinical pharmacokinetic outcomes associated with peak--trough-based versus trough-only-based vancomycin therapeutic drug monitoring approachesVariableTrough-only-monitoring groupPeak--trough-monitoring group*p* value^a^(*n* = 35)(*n* = 30)Pharmacokinetic parameters at treatment initiation *V*~d~ (L), mean ± SD48.5 ± 10.751.14 ± 9.960.311 *K*~e~ (h^−1^), mean ± SD0.094 ± 0.050.089 ± 0.0510.702 Cl (L/h), mean ± SD4.15 ± 2.224.24 ± 2.200.861 *t*~1/2~ (h), median \[IQR\]8.01 \[11.12\]7.23 \[9.75\]0.722 CrCl (L/h), median \[IQR\]6.51 \[3.44\]6.45 \[3.12\]0.374 AUC per initial^b^ dose (mg\*h/L), median \[IQR\]227 \[195.6\]228 \[273.01\]0.590Initial^b^ vancomycin serum concentrations (mg/L), median \[IQR\] Trough-19 \[8.3\]8.4 \[12.9\]0.732 Peak25 \[10\]27.9 \[17.8\]0.863 Random-118.9 \[9.4\]18 \[18.1\]0.837 Random-211.9 \[8.7\]11.1 \[13.28\]0.638 Trough-210.6 \[10.5\]8.9 \[15.1\]0.844Interpretation of initial^b^ peak vancomycin concentrations, *n* (%)^d^ Therapeutic27 (77.1)17 (60.7)0.158 Non-therapeutic8 (22.9)11 (39.3)Interpretation of initial^b^ vancomycin trough concentrations, *n* (%) Therapeutic6 (17.1)7 (23.3)0.534 Non-therapeutic29 (82.9)23 (76.7) Minimum number of dose adjustments required to first therapeutic serum concentrations, median \[min--max\]2 \[1--5\]1 \[1--3\]0.105Overall vancomycin dosing requirements Single dose (mg/dose), mean ± SD1385.71 ± 530.621015 ± 332.2210.001 Single dose (mg/kg/dose), mean ± SD19.03 ± 7.7614.09 ± 5.680.005 Total daily dose (mg/day), mean ± SD3834.49 ± 1,362.832907 ± 1,416.080.009 Total daily dose (mg/kg/day), mean ± SD52.83 ± 21.5940.78 ± 21.250.027 Cumulative doses received (mg), mean ± SD26,275 ± 24,19019,753 ± 21,8930.192Vancomycin dosing interval, *n* (%) Q6 h6 (17.1)11 (36.7)0.091 Q8 h16 (45.7)12 (40) Q12 h13 (37.1)4 (13.4) Q18 h0 (0)1 (3.3) Q24 h0 (0)1 (3.3) Q36 h0 (0)1 (3.3)Vancomycin infusion duration, *n* (%) Infused over 0.5 h1 (2.9)0 (0)0.297 Infused over 1 h19 (54.3)22 (73.3) Infused over 1.5 h10 (28.5)8 (26.7) Infused over 2.5 h2 (5.7)0 (0) Infused over 3 h2 (5.7)0 (0) Infused over 4 h1 (2.9)0 (0) AUC per TDM adjusted dose(mg\*h/L), median \[IQR\]270 \[156.02\]223 \[168.82\]0.590 AUC~24~/MIC, median \[IQR\]772 \[412.95\]708 \[260.87\]0.762 Post-dose adjustment peak concentration (mg/L), mean ± SD35.94 ± 7.730.38 ± 5.170.021 Post-dose adjustment trough concentration (mg/L), mean ± SD16.8 ± 3.0915.6 ± 3.490.596Interpretation of post-dose adjustment^c^ peak concentrations, *n* (%)^d^ Therapeutic29 (69)32 (94.1)0.006 Subtherapeutic13 (31)2 (5.9)Interpretation of post-dose adjustment^c^ trough concentrations, *n* (%) Therapeutic25 (44.6)20 (54.1)0.665 Subtherapeutic19 (33.9)10 (27) Supratherapeutic12 (21.4)7 (18.9)^a^Chi-squared test, Mann--Whitney *U*-test or Student's *t*-test^b^Initial represents pre-TDM doses and concentrations^c^56 dose adjustments were applied in the trough-only arm while 37 dose adjustments were applied in the peak--trough arm^d^Missing valuesFig. 1Vancomycin dosing requirements of peak--trough-based versus trough-only-based vancomycin therapeutic drug monitoring recipients

Association Between Vancomycin AUC~24~/MIC and Cure {#Sec20}
---------------------------------------------------

CART identified CL~CR~ \< 7.85 L/h, AUC~24/~MIC, and the type of vancomycin TDM approach as significant determinants of therapeutic outcomes with 100, 58.4 and 45.8% normalized importance to the model, respectively. Maintaining AUC~24~/MIC between 565 and 1256 has been associated with cure. All subjects who achieved an AUC~24~/MIC ≤ 1256 and received peak--trough-based vancomycin TDM achieved clinical success rates \[100%, *n* = 19\]. Maintenance of AUC~24~/MIC \> 565 was identified to be correlated with cure in trough-only-based TDM recipients \[84.6%, *n* = 11\]. No minimum AUC~24~/MIC breakpoint was detected by CART in the peak--trough-based group. The predictive performance was high (88.6%) with low misclassification risks (11.4%), suggesting robustness.

Discussion {#Sec21}
==========

To our knowledge, this is the first pragmatic head-to-head RCT that (1) prospectively compared two routinely used vancomycin TDM approaches; (2) reported MENA-specific AUC~24~/MIC targets; and (3) identified a maximum AUC~24~/MIC threshold for clinical benefit. Studies have suggested that vancomycin TDM was associated with higher clinical success rates and less nephrotoxicity compared to non-TDM groups \[[@CR31], [@CR51]\]. To date, studies in this area compared vancomycin TDM recipients with non-TDM recipients, and were mostly based on observational research designs \[[@CR31]\]. In addition, no studies reported MENA-specific AUC~24~/MIC targets. The present pragmatic RCT aimed to address these questions.

Despite similar AUC~24~ exposures, peak--trough-based TDM was associated with higher cure rates compared to trough-only-based TDM. This unexpected finding can be interpreted in two ways. First, it questions whether AUC~24~/MIC is the optimal vancomycin pharmacokinetic--pharmacodynamic target. Fukumori's group reported the area under the trough level as a novel pharmacokinetic--pharmacodynamic parameter that more strongly correlates with vancomycin clinical efficacy compared to AUC~24~ \[[@CR52]\]. Second, it suggests that cure may be more associated with the extent of consistency, sustainability and fluctuations of vancomycin exposure during the course of therapy, rather than a total single exposure estimate. This notion serves as the basis for studies advocating the administration of vancomycin as continuous infusion, rather than intermittent infusion \[[@CR53]--[@CR55]\]. Compared to intermittent infusion, continuous infusion resulted in more consistent and sustained exposure at the infection site, despite similar AUCs \[[@CR54]\]. Furthermore, continuous infusion achieved target concentrations faster and was associated with less serum fluctuations \[[@CR55]\]. Collectively these studies align with the finding that a minimum cure breakpoint (AUC~24~/MIC \> 565) was only detected in the trough-only TDM arm, while peak--trough-based vancomycin dosing was not associated with a minimum threshold. This suggests that peak--trough-based vancomycin dosing, using the specified peak/trough targets, is associated with more sustained and consistent vancomycin exposure that resulted in achieving the minimum AUC~24~/MIC threshold for cure at most times, unlike trough-only based dosing. Vancomycin continuous infusion is not feasible for all clinical settings or patient situations. For example, a patient may be on other vancomycin-incompatible intravenous therapy. Indeed, the peak--trough-based approach may serve as a more practical alternative to continuous infusion that needs to be explored in future studies.

Maintaining AUC~24~/MIC between 565 and 1256 has been associated with cure. This breakpoint is higher than the minimum AUC~24~/MIC cure breakpoints that ranged from 398 to 451 in seven observational cohort studies \[[@CR19]\]. Additionally, this work is the first to identify a maximum AUC~24~/MIC cure threshold that, if exceeded, no extra clinical benefit is likely as long as the CL~CR~ is \< 130 mL/min. This concurs with the emerging concept of ARC (CL~CR~ \> 120--150 mL/min), that is associated with decreased vancomycin exposure and negative clinical outcomes \[[@CR56]--[@CR60]\]. Although studies reported that targeting, higher AUC~24~/MIC ratios was associated with better clinical outcomes \[[@CR19], [@CR61]\], the question regarding a maximum AUC~24~/MIC for clinical benefit remained unanswered in the current literature. It should be carefully noted that pharmacokinetic--pharmacodynamic targets (i.e., AUC~24~/MIC) serve only for clinical efficacy outcomes while absolute vancomycin exposure measures should be monitored for safety \[[@CR1], [@CR3], [@CR62], [@CR63]\].

Emerging evidence suggests the promising clinical usefulness of the peak--trough-based vancomycin TDM approach \[[@CR22], [@CR64], [@CR65]\], and questions the clinical benefit of trough-only-based vancomycin dosing \[[@CR61], [@CR66], [@CR67]\]. Consistent with other studies, this RCT suggests that peak--trough-based vancomycin dosing may be associated with lower vancomycin exposure, LOS and dose adjustments, which needs to be confirmed in larger scale trials. Finch et al. reported that 2-concentration-based AUC-guided vancomycin dosing resulted in less vancomycin exposure, total daily doses and nephrotoxicity versus trough-only-guided dosing \[[@CR22]\]. Similar clinical benefits of vancomycin peak concentration monitoring have been suggested elsewhere \[[@CR64], [@CR65]\]. Peak--trough-based TDM allowed significantly better attainment of therapeutic vancomycin concentrations \[[@CR64]\]. It has been reported that vancomycin-related ADRs (i.e., nephrotoxicity and neutropenia) may be related to exposure \[[@CR23], [@CR47], [@CR48], [@CR68]--[@CR72]\], with trough concentrations \> 15 mg/L having a significantly higher risk \[[@CR69]\]. According to a meta-analysis of 17 observational studies, vancomycin dosing that targeted higher trough concentrations (\> 15 mg/L) was associated with significantly more nephrotoxicity and no significant improvement in mortality or cure rates \[[@CR66]\]. In deep-seated MRSA, trough concentrations \> 15 mg/L did not result in shorter LOS, lower mortality rates, or higher treatment success rates versus trough concentrations \< 15 mg/L \[[@CR67]\]. In fact, vancomycin trough concentrations \> 15 mg/L were associated with a higher incidence of nephrotoxicity \[[@CR67]\]. A meta-analysis of 14 observational studies showed that vancomycin dosing based on trough concentration targets (15--20 mg/L) was not associated with better clinical outcomes in mortality, bacteremia persistence and treatment failure \[[@CR61]\]. Therefore, peak--trough-based vancomycin dosing provides a potential strategy to decrease vancomycin exposure, which will reflect into lower medication utilization, less vancomycin-related ADRs, and decreased emergence of vancomycin-resistant strains. Furthermore, the possibly lower LOS with peak--trough-based dosing would potentially result in a lower incidence of nosocomial infections. Thus, this approach provides a potential strategy to maximize clinical outcomes with vancomycin treatment, as well as decrease the economic burden on healthcare systems.

This study has several strengths. First, the present RCT is of a pragmatic nature. The key feature of pragmatic designs is the ability to assess the effectiveness of an intervention in routine situations to maximize the external validity of the study findings \[[@CR73]\]. Due to the limited generalizability of exploratory RCTs to routine clinical practice, the concept of pragmatism has emerged during the past decades \[[@CR73]--[@CR75]\]. Exploratory RCTs are conducted under ideal circumstances in which an intervention is more likely to work, which is not how real-life situations are in clinical settings; thus, they possess limited generalizability and may fail in many routine clinical situations \[[@CR73]\]. Therefore, it has been reported that the plethora of exploratory RCTs are of limited use to healthcare policymakers and clinicians \[[@CR75]\]. Due to the pragmatic nature of this study, the researchers did not intervene on indication appropriateness and initial dosing of vancomycin; suspected or confirmed Gram-positive infections requiring vancomycin treatment were included, with no restrictions to MRSA like other AUC studies. The study setting included multiple centers and wards in order to be reflective of the variabilities in clinical practice. An important observation is the lack of initial vancomycin target attainment with physician-initiated dosing at most times, which may be due to deviations from the guideline-recommended empiric doses in our clinical setting. The reasons for such non-compliance need to be explored in future audits. In addition, no restrictions on infection type, critical illness state, pharmacotherapeutic or mechanical co-interventions were applied. Thus, the implications of the study findings are of clinical relevance, as it tested effectiveness rather than efficacy alone. Second, the prospective nature of the study allowed accurate vancomycin dosing and blood specimen collection. The accuracy of sampling times and dosing assures the internal validity of clinical pharmacokinetic studies. Unlike most clinical evaluations that estimated the AUC based on estimated renal clearance, which does not accurately predict vancomycin clearance \[[@CR23]\], the present work used actual individualized vancomycin clearance to estimate the AUC. Together, these aspects suggest high internal validity of the study, with considerable generalizability.

The present findings need to be interpreted with caution due to some important limitations. This RCT was of limited sample size and was unblinded. The exact MICs were not available for all subjects since many received vancomycin as empiric therapy. For subjects with confirmed sensitive cultures, HMC laboratories reported MIC as 1 mg/L at all instances with values of \< 1 mg/L rounded to 1 mg/L. Future larger scale double-blinded pragmatic RCTs are needed to confirm these findings.

Conclusion {#Sec22}
==========

In conclusion, this is the first head-to-head pragmatic RCT that compared peak--trough-based versus trough-only-based vancomycin TDM approaches. Compared to trough-only-based vancomycin TDM, peak--trough-based vancomycin TDM strategy was associated with higher cure rates and less vancomycin doses. Furthermore, maintaining an AUC~24~/MIC between 565 and 1256 was associated with cure. Future larger scale trials are warranted to confirm these study findings.
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